Skip to main content Skip to footer
HomeHome
 
  • Startseite
  • Patentrecherche

    Patentwissen

    Unsere Patentdatenbanken und Recherchetools

    Zur Übersicht 

    • Übersicht
    • Technische Information
      • Übersicht
      • Espacenet - Patentsuche
      • Europäischer Publikationsserver
      • EP-Volltextrecherche
    • Rechtliche Information
      • Übersicht
      • Europäisches Patentregister
      • Europäisches Patentblatt
      • European Case Law Identifier Sitemap
      • Einwendungen Dritter
    • Geschäftsinformationen
      • Übersicht
      • PATSTAT
      • IPscore
      • Technologieanalyseberichte
    • Daten
      • Übersicht
      • Technology Intelligence Platform
      • Linked open EP data
      • Massendatensätze
      • Web-Dienste
      • Datenbestände, Codes und Statistiken
    • Technologieplattformen
      • Übersicht
      • Kunststoffe im Wandel
      • Innovationen im Wassersektor
      • Innovationen im Weltraumsektor
      • Technologien zur Bekämpfung von Krebs
      • Technologien zur Brandbekämpfung
      • Saubere Energietechnologien
      • Kampf gegen Corona
    • Nützliche Informationsquellen
      • Übersicht
      • Zum ersten Mal hier? Was ist Patentinformation?
      • Patentinformation aus Asien
      • Patentinformationszentren (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Wirtschaft und Statistik
      • Patentinformationen rund um den einheitlichen Patentschutz
    Bild
    Plastics in Transition

    Technologieanalysebericht zur Plastikabfallwirtschaft

  • Anmelden eines Patents

    Anmelden eines Patents

    Praktische Informationen über Anmelde- und Erteilungsverfahren.

    Zur Übersicht 

    • Übersicht
    • Europäischer Weg
      • Übersicht
      • Leitfaden zum europäischen Patent
      • Einsprüche
      • Mündliche Verhandlung
      • Beschwerden
      • Einheitspatent & Einheitliches Patentgericht
      • Nationale Validierung
      • Antrag auf Erstreckung/Validierung
    • Internationaler Weg (PCT)
      • Übersicht
      • Euro-PCT-Leitfaden: PCT-Verfahren im EPA
      • Beschlüsse und Mitteilungen des EPA
      • PCT-Bestimmungen und Informationsquellen
      • Erstreckungs-/Validierungsantrag
      • Programm für verstärkte Partnerschaft
      • Beschleunigung Ihrer PCT-Anmeldung
      • Patent Prosecution Highway (PPH)
      • Schulungen und Veranstaltungen
    • Nationale Anmeldungen
    • Zugelassenen Vertreter suchen
    • MyEPO Services
      • Übersicht
      • Unsere Dienste verstehen
      • Zugriff erhalten
      • Bei uns einreichen
      • Akten interaktiv bearbeiten
      • Verfügbarkeit der Online-Dienste
    • Formblätter
      • Übersicht
      • Prüfungsantrag
    • Gebühren
      • Übersicht
      • Europäische Gebühren (EPÜ)
      • Internationale Gebühren (PCT)
      • Einheitspatentgebühren (UP)
      • Gebührenzahlung und Rückerstattung
      • Warnung

    UP

    Erfahren Sie, wie das Einheitspatent Ihre IP-Strategie verbessern kann

  • Recht & Praxis

    Recht & Praxis

    Europäisches Patentrecht, Amtsblatt und andere Rechtstexte

    Zur Übersicht 

    • Übersicht
    • Rechtstexte
      • Übersicht
      • Europäisches Patentübereinkommen
      • Amtsblatt
      • Richtlinien
      • Erstreckungs-/ Validierungssyste
      • Londoner Übereinkommen
      • Nationales Recht zum EPÜ
      • Système du brevet unitaire
      • Nationale Maßnahmen zum Einheitspatent
    • Gerichtspraxis
      • Übersicht
      • Symposium europäischer Patentrichter
    • Nutzerbefragungen
      • Übersicht
      • Laufende Befragungen
      • Abgeschlossene Befragungen
    • Harmonisierung des materiellen Patentrechts
      • Übersicht
      • The Tegernsee process
      • Gruppe B+
    • Konvergenz der Verfahren
    • Optionen für zugelassene Vertreter
    Bild
    Law and practice scales 720x237

    Informieren Sie sich über die wichtigsten Aspekte ausgewählter BK-Entscheidungen in unseren monatlichen „Abstracts of decisions“

  • Neues & Veranstaltungen

    Neues & Veranstaltungen

    Aktuelle Neuigkeiten, Podcasts und Veranstaltungen.

    Zur Übersicht 

     

    • Übersicht
    • News
    • Veranstaltungen
    • Europäischer Erfinderpreis
      • Übersicht
      • Die bedeutung von morgen
      • Über den Preis
      • Kategorien und Preise
      • Lernen Sie die Finalisten kennen
      • Nominierungen
      • European Inventor Network
      • Preisverleihung 2024
    • Young Inventor Prize
      • Übersicht
      • Über den Preis
      • Nominierungen
      • Die jury
      • Die Welt, neu gedacht
    • Pressezentrum
      • Übersicht
      • Patent Index und Statistiken
      • Pressezentrum durchsuchen
      • Hintergrundinformation
      • Copyright
      • Pressekontakt
      • Rückruf Formular
      • Presseinfos per Mail
    • Innovation und Patente im Blickpunkt
      • Übersicht
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Forschungseinrichtungen
      • Women inventors
      • Lifestyle
      • Raumfahrt und Satelliten
      • Zukunft der Medizin
      • Werkstoffkunde
      • Mobile Kommunikation: Das große Geschäft mit kleinen Geräten
      • Biotechnologiepatente
      • Patentklassifikation
      • Digitale Technologien
      • Die Zukunft der Fertigung
      • Books by EPO experts
    • Podcast "Talk innovation"

    Podcast

    Von der Idee zur Erfindung: unser Podcast informiert Sie topaktuell in Sachen Technik und IP

  • Lernen

    Lernen

    Europäische Patentakademie – unser Kursportal für Ihre Fortbildung

    Zur Übersicht 

    • Übersicht
    • Schulungsaktivitäten und Lernpfade
      • Übersicht
      • Schulungsaktivitäten
      • Lernpfade
    • EEP und EPVZ
      • Übersicht
      • EEP – Europäische Eignungsprüfung
      • EPVZ – Europäisches Patentverwaltungszertifikat
      • CSP – Programm zur Unterstützung von Bewerbern
    • Lernmaterial nach Interesse
      • Übersicht
      • Patenterteilung
      • Technologietransfer und -verbreitung
      • Durchsetzung
    • Lernmaterial nach Profil
      • Übersicht
      • Geschäftswelt und IP
      • EEP und EPVZ Bewerber
      • Justiz
      • Nationale Ämter und IP-Behörden
      • Patentanwaltskanzleien
      • Lehre und Forschung
    Bild
    Patent Academy catalogue

    Werfen Sie einen Blick auf das umfangreiche Lernangebot im Schulungskatalog der Europäischen Patentakademie

  • Über uns

    Über uns

    Erfahren Sie mehr über Tätigkeit, Werte, Geschichte und Vision des EPA

    Zur Übersicht 

    • Übersicht
    • Das EPA auf einen Blick
    • 50 Jahre Europäisches Patentübereinkommen
      • Übersicht
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kinderwettbewerb für kollektive Kunst
    • Rechtsgrundlagen und Mitgliedstaaten
      • Übersicht
      • Rechtsgrundlagen
      • Mitgliedstaaten der Europäischen Patentorganisation
      • Erstreckungsstaaten
      • Validierungsstaaten
    • Verwaltungsrat und nachgeordnete Organe
      • Übersicht
      • Kommuniqués
      • Kalender
      • Dokumente und Veröffentlichungen
      • Der Verwaltungsrat der Europäischen Patentorganisation
    • Unsere Grundsätze und Strategie
      • Übersicht
      • Auftrag, Vision und Werte
      • Strategischer Plan 2028
      • Auf dem Weg zu einer neuen Normalität
    • Führung und Management
      • Übersicht
      • Präsident António Campinos
      • Managementberatungsausschuss
    • Sustainability at the EPO
      • Übersicht
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Dienste & Aktivitäten
      • Übersicht
      • Unsere Dienste & Struktur
      • Qualität
      • Nutzerkonsultation
      • Europäische und internationale Zusammenarbeit
      • Europäische Patentakademie
      • Chefökonom
      • Ombudsstelle
      • Meldung von Fehlverhalten
    • Beobachtungsstelle für Patente und Technologie
      • Übersicht
      • Akteure im Innovationsbereich
      • Politisches Umfeld und Finanzierung
      • Tools
      • Über die Beobachtungsstelle
    • Beschaffung
      • Übersicht
      • Beschaffungsprognose
      • Das EPA als Geschäftspartner
      • Beschaffungsverfahren
      • Nachhaltiger Beschaffungsstandard
      • Registrierung zum eTendering und elektronische Signaturen
      • Beschaffungsportal
      • Rechnungsstellung
      • Allgemeine Bedingungen
      • Archivierte Ausschreibungen
    • Transparenzportal
      • Übersicht
      • Allgemein
      • Humankapital
      • Umweltkapital
      • Organisationskapital
      • Sozial- und Beziehungskapital
      • Wirtschaftskapital
      • Governance
    • Statistics and trends
      • Übersicht
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • Die Geschichte des EPA
      • Übersicht
      • 1970er-Jahre
      • 1980er-Jahre
      • 1990er-Jahre
      • 2000er-Jahre
      • 2010er-Jahre
      • 2020er Jahre
    • Die EPA Kunstsammlung
      • Übersicht
      • Die Sammlung
      • Let's talk about art
      • Künstler
      • Mediathek
      • What's on
      • Publikationen
      • Kontakt
      • Kulturraum A&T 5-10
      • "Lange Nacht"
    Bild
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Verfolgen Sie die neuesten Technologietrends mit unserem Patentindex

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • Sind Patente Neuland für Sie?
  • Sind Patente Neuland für Sie?
    • Go back
    • Patente für Ihr Unternehmen?
    • Warum ein Patent?
    • Was ist Ihre zündende Idee?
    • Sind Sie bereit?
    • Darum geht es
    • Der Weg zum Patent
    • Ist es patentierbar?
    • Ist Ihnen jemand zuvorgekommen?
    • Patentquiz
    • Video zum Einheitspatent
  • Patentrecherche
    • Go back
    • Übersicht
    • Technische Information
      • Go back
      • Übersicht
      • Espacenet - Patentsuche
        • Go back
        • Übersicht
        • Datenbanken der nationalen Ämter
        • Global Patent Index (GPI)
        • Versionshinweise
      • Europäischer Publikationsserver
        • Go back
        • Übersicht
        • Versionshinweise
        • Konkordanzliste für Euro-PCT-Anmeldungen
        • EP-Normdatei
        • Hilfe
      • EP-Volltextrecherche
    • Rechtliche Information
      • Go back
      • Übersicht
      • Europäisches Patentregister
        • Go back
        • Übersicht
        • Versionshinweise: Archiv
        • Dokumentation zu Register
          • Go back
          • Übersicht
          • Datenverfügbarkeit für Deep Links
          • Vereinigtes Register
          • Ereignisse im Register
      • Europäisches Patentblatt
        • Go back
        • Übersicht
        • Patentblatt herunterladen
        • Recherche im Europäischen Patentblatt
        • Hilfe
      • European Case Law Identifier Sitemap
      • Einwendungen Dritter
    • Geschäftsinformationen
      • Go back
      • Übersicht
      • PATSTAT
      • IPscore
        • Go back
        • Versionshinweise
      • Technologieanalyseberichte
    • Daten
      • Go back
      • Übersicht
      • Technology Intelligence Platform
      • Linked open EP data
      • Massendatensätze
        • Go back
        • Übersicht
        • Manuals
        • Sequenzprotokolle
        • Nationale Volltextdaten
        • Daten des Europäischen Patentregisters
        • Weltweite bibliografische Daten des EPA (DOCDB)
        • EP-Volltextdaten
        • Weltweite Rechtsereignisdaten des EPA (INPADOC)
        • Bibliografische Daten von EP-Dokumenten (EBD)
        • Entscheidungen der Beschwerdekammern des EPA
      • Web-Dienste
        • Go back
        • Übersicht
        • Open Patent Services (OPS)
        • Europäischer Publikationsserver (Web-Dienst)
      • Datenbestände, Codes und Statistiken
        • Go back
        • Wöchentliche Aktualisierungen
        • Regelmäßige Aktualisierungen
    • Technologieplattformen
      • Go back
      • Kunststoffe im Wandel
        • Go back
        • Overview
        • Verwertung von Plastikabfällen
        • Recycling von Plastikabfällen
        • Alternative Kunststoffe
      • Übersicht
      • Innovative Wassertechnologien
        • Go back
        • Overview
        • Sauberes Wasser
        • Schutz vor Wasser
      • Innovationen im Weltraumsektor
        • Go back
        • Übersicht
        • Kosmonautik
        • Weltraumbeobachtung
      • Technologien zur Bekämpfung von Krebs
        • Go back
        • Übersicht
        • Prävention und Früherkennung
        • Diagnostik
        • Therapien
        • Wohlergehen und Nachsorge
      • Technologien zur Brandbekämpfung
        • Go back
        • Übersicht
        • Branderkennung und -verhütung
        • Feuerlöschen
        • Schutzausrüstung
        • Technologien für die Sanierung nach Bränden
      • Saubere Energietechnologien
        • Go back
        • Übersicht
        • Erneuerbare Energien
        • CO2-intensive Industrien
        • Energiespeicherung und andere Enabling-Technologien
      • Kampf gegen Corona
        • Go back
        • Übersicht
        • Impfstoffe und Therapeutika
          • Go back
          • Übersicht
          • Impfstoffe
          • Übersicht über Therapieansätze für COVID-19
          • Kandidaten für antivirale Therapeutika
          • Nukleinsäuren zur Behandlung von Coronavirus-Infektionen
        • Diagnose und Analyse
          • Go back
          • Übersicht
          • Protein-und Nukleinsäure-Nachweis
          • Analyseprotokolle
        • Informatik
          • Go back
          • Übersicht
          • Bioinformatik
          • Medizinische Informatik
        • Technologien für die neue Normalität
          • Go back
          • Übersicht
          • Geräte, Materialien und Ausrüstung
          • Verfahren, Maßnahmen und Aktivitäten
          • Digitale Technologien
        • Erfinderinnen und Erfinder gegen das Coronavirus
    • Nützliche Informationsquellen
      • Go back
      • Übersicht
      • Zum ersten Mal hier? Was ist Patentinformation?
        • Go back
        • Übersicht
        • Grundlegende Definitionen
        • Patentklassifikation
          • Go back
          • Übersicht
          • Gemeinsame Patentklassifikation
        • Patentfamilien
          • Go back
          • Übersicht
          • Einfache DOCDB Patentfamilie
          • Erweiterte INPADOC Patentfamilie
        • Daten zu Rechtsstandsereignissen
          • Go back
          • Übersicht
          • INPADOC-Klassifikationssystem
      • Patentinformation aus Asien
        • Go back
        • Übersicht
        • China (CN)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinesisch-Taipei (TW)
          • Go back
          • Übersicht
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Indien (IN)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russische Föderation (RU)
          • Go back
          • Übersicht
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patentinformationszentren (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Wirtschaft und Statistik
      • Patentinformationen rund um den einheitlichen Patentschutz
  • Anmelden eines Patents
    • Go back
    • Übersicht
    • Europäischer Weg
      • Go back
      • Übersicht
      • Leitfaden zum europäischen Patent
      • Einsprüche
      • Mündliche Verhandlung
        • Go back
        • Kalender der mündlichen Verhandlungen
          • Go back
          • Kalender der mündlichen Verhandlungen
          • Technische Richtlinien
          • Zugang für die Öffentlichkeit zum Beschwerdeverfahren
          • Zugang für die Öffentlichkeit zum Einspruchsverfahren
      • Beschwerden
      • Einheitspatent & Einheitliches Patentgericht
        • Go back
        • Einheitspatent
          • Go back
          • Übersicht
          • Rechtlicher Rahmen
          • Wesentliche Merkmale
          • Beantragung eines Einheitspatents
          • Kosten eines Einheitspatents
          • Übersetzungsregelungen und Kompensationssystem
          • Starttermin
          • Introductory brochures
        • Übersicht
        • Einheitliches Patentgericht
      • Nationale Validierung
      • Erstreckungs- /Validierungsantrag
    • Internationaler Weg
      • Go back
      • Übersicht
      • Euro-PCT-Leitfaden
      • Eintritt in die europäische Phase
      • Beschlüsse und Mitteilungen
      • PCT-Bestimmungen und Informationsquellen
      • Erstreckungs-/Validierungsantrag
      • Programm für verstärkte Partnerschaft
      • Beschleunigung Ihrer PCT-Anmeldung
      • Patent Prosecution Highway (PPH)
        • Go back
        • Programm "Patent Prosecution Highway" (PPH) - Übersicht
      • PCT: Schulungen und Veranstaltungen
    • Nationaler Weg
    • MyEPO Services
      • Go back
      • Übersicht
      • Unsere Dienste verstehen
        • Go back
        • Übersicht
        • Exchange data with us using an API
          • Go back
          • Versionshinweise
      • Zugriff erhalten
        • Go back
        • Übersicht
        • Versionshinweise
      • Bei uns einreichen
        • Go back
        • Bei uns einreichen
        • Wenn unsere Dienste für die Online-Einreichung ausfallen
        • Versionshinweise
      • Akten interaktiv bearbeiten
        • Go back
        • Versionshinweise
      • Verfügbarkeit der Online-Dienste
    • Gebühren
      • Go back
      • Übersicht
      • Europäische Gebühren (EPÜ)
        • Go back
        • Übersicht
        • Beschlüsse und Mitteilungen
      • Internationale Gebühren (PCT)
        • Go back
        • Ermäßigung der Gebühren
        • Gebühren für internationale Anmeldungen
        • Beschlüsse und Mitteilungen
        • Übersicht
      • Einheitspatentgebühren (UP)
        • Go back
        • Übersicht
        • Beschlüsse und Mitteilungen
      • Gebührenzahlung und Rückerstattung
        • Go back
        • Übersicht
        • Zahlungsarten
        • Erste Schritte
        • FAQs und sonstige Anleitungen
        • Technische Informationen für Sammelzahlungen
        • Beschlüsse und Mitteilungen
        • Versionshinweise
      • Warnung
    • Formblätter
      • Go back
      • Prüfungsantrag
      • Übersicht
    • Zugelassenen Vertreter suchen
  • Recht & Praxis
    • Go back
    • Übersicht
    • Rechtstexte
      • Go back
      • Übersicht
      • Europäisches Patentübereinkommen
        • Go back
        • Übersicht
        • Archiv
          • Go back
          • Übersicht
          • Dokumentation zur EPÜ-Revision 2000
            • Go back
            • Übersicht
            • Diplomatische Konferenz für die Revision des EPÜ
            • "Travaux préparatoires" (Vorarbeiten)
            • Neufassung
            • Übergangsbestimmungen
            • Ausführungsordnung zum EPÜ 2000
            • Gebührenordnung
            • Ratifikationen und Beitritte
          • Travaux Préparatoires EPÜ 1973
      • Amtsblatt
      • Richtlinien
        • Go back
        • Übersicht
        • EPÜ Richtlinien
        • PCT-EPA Richtlinien
        • Richtlinien für das Einheitspatent
        • Überarbeitung der Richtlinien
        • Ergebnisse der Konsultation
        • Zusammenfassung der Nutzerbeiträge
        • Archiv
      • Erstreckungs-/Validierungssystem
      • Londoner Übereinkommen
      • Nationales Recht zum EPÜ
        • Go back
        • Übersicht
        • Archiv
      • Einheitspatentsystem
        • Go back
        • Travaux préparatoires to UP and UPC
      • Nationale Maßnahmen zum Einheitspatent
    • Gerichtspraxis
      • Go back
      • Übersicht
      • Symposium europäischer Patentrichter
    • Nutzerbefragungen
      • Go back
      • Übersicht
      • Laufende Befragungen
      • Abgeschlossene Befragungen
    • Harmonisierung des materiellen Patentrechts
      • Go back
      • Übersicht
      • The Tegernsee process
      • Gruppe B+
    • Konvergenz der Verfahren
    • Optionen für zugelassene Vertreter
  • Neues & Veranstaltungen
    • Go back
    • Übersicht
    • News
    • Veranstaltungen
    • Europäischer Erfinderpreis
      • Go back
      • The meaning of tomorrow
      • Übersicht
      • Über den Preis
      • Kategorien und Preise
      • Lernen Sie die Erfinder kennen
      • Nominierungen
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • Preisverleihung 2024
    • Young Inventors Prize
      • Go back
      • Übersicht
      • Über den Preis
      • Nominierungen
      • Die Jury
      • Die Welt, neu gedacht
      • Preisverleihung 2025
    • Pressezentrum
      • Go back
      • Übersicht
      • Patent Index und Statistiken
      • Pressezentrum durchsuchen
      • Hintergrundinformation
        • Go back
        • Übersicht
        • Europäisches Patentamt
        • Fragen und Antworten zu Patenten im Zusammenhang mit dem Coronavirus
        • Fragen und Antworten zu Pflanzenpatenten
      • Copyright
      • Pressekontakt
      • Rückruf Formular
      • Presseinfos per Mail
    • Im Blickpunkt
      • Go back
      • Übersicht
      • Wasserbezogene Technologien
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Übersicht
        • CodeFest 2024 zu generativer KI
        • Codefest 2023 zu grünen Kunststoffen
      • Green tech in focus
        • Go back
        • Übersicht
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Forschungseinrichtungen
      • Women inventors
      • Lifestyle
      • Raumfahrt und Satelliten
        • Go back
        • Weltraumtechnologie und Patente
        • Übersicht
      • Gesundheit
        • Go back
        • Übersicht
        • Medizintechnik und Krebs
        • Personalised medicine
      • Werkstoffkunde
        • Go back
        • Übersicht
        • Nanotechnologie
      • Mobile Kommunikation
      • Biotechnologie
        • Go back
        • Rot, weiß oder grün
        • Übersicht
        • Die Rolle des EPA
        • Was ist patentierbar?
        • Biotechnologische Erfindungen und ihre Erfinder
      • Patentklassifikation
        • Go back
        • Übersicht
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Übersicht
          • External partners
          • Updates on Y02 and Y04S
      • Digitale Technologien
        • Go back
        • Übersicht
        • Über IKT
        • Hardware und Software
        • Künstliche Intelligenz
        • Vierte Industrielle Revolution
      • Additive Fertigung
        • Go back
        • Übersicht
        • Die additive Fertigung
        • Innovation durch AM
      • Books by EPO experts
    • Podcast
  • Lernen
    • Go back
    • Übersicht
    • Schulungsaktivitäten und Lernpfade
      • Go back
      • Übersicht
      • Schulungsaktivitäten: Arten und Formate
      • Lernpfade
    • EEP und EPVZ
      • Go back
      • Übersicht
      • EEP – Europäische Eignungsprüfung
        • Go back
        • Übersicht
        • Compendium
          • Go back
          • Übersicht
          • Aufgabe F
          • Aufgabe A
          • Aufgabe B
          • Aufgabe C
          • Aufgabe D
          • Vorprüfung
        • Erfolgreiche Bewerber
        • Archiv
      • EPVZ – Europäisches Patentverwaltungszertifikat
      • CSP – Programm zur Unterstützung von Bewerbern
    • Angebot für bestimmte Interessengebiete
      • Go back
      • Übersicht
      • Patenterteilung
      • Technologietransfer und -verbreitung
      • Patentdurchsetzung und Streitregelung
    • Angebot für bestimmte Zielgruppen
      • Go back
      • Übersicht
      • Geschäftswelt und IP
        • Go back
        • Übersicht
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Fallstudien zum Technologietransfer
          • Fallstudien zu wachstumsstarken Technologien
        • Inventor's handbook
          • Go back
          • Übersicht
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Übersicht
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Übersicht
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EEP und EPVZ Bewerber
        • Go back
        • Übersicht
        • Denkaufgaben zu Aufgabe F
        • Tägliche Fragen zur Aufgabe D
        • Europäische Eignungsprüfung - Leitfaden zur Vorbereitung
        • EPVZ
      • Richter, Anwälte und Staatsanwälte
        • Go back
        • Übersicht
        • Compulsory licensing in Europe
        • Die Zuständigkeit europäischer Gerichte bei Patentstreitigkeiten
      • Nationale Ämter und IP-Behörden
        • Go back
        • Übersicht
        • Lernpfad für Patentprüfer der nationalen Ämter
        • Lernpfad für Formalsachbearbeiter und Paralegals
      • Patentanwaltskanzleien
      • Hochschulen, Forschungseinrichtungen und Technologietransferstellen
        • Go back
        • Übersicht
        • Modularer IP-Ausbildungsrahmen (MIPEF)
        • Programm "Pan-European-Seal für junge Fachkräfte"
          • Go back
          • Übersicht
          • Für Studierende
          • Für Hochschulen
            • Go back
            • Übersicht
            • IP-Schulungsressourcen
            • Hochschulmitgliedschaften
          • Unsere jungen Fachkräfte
          • Beruflicher Entwicklungsplan
        • Akademisches Forschungsprogramm (ARP)
          • Go back
          • Übersicht
          • Abgeschlossene Forschungsprojekte
          • Laufende Forschungsprojekte
        • IP Teaching Kit
          • Go back
          • Übersicht
          • Download modules
        • Handbuch für die Gestaltung von IP-Kursen
        • PATLIB Wissenstransfer nach Afrika
          • Go back
          • Die PATLIB-Initiative "Wissenstransfer nach Afrika" (KT2A)
          • KT2A-Kernaktivitäten
          • Erfolgsgeschichte einer KT2A-Partnerschaft: PATLIB Birmingham und Malawi University of Science and Technology
  • Über uns
    • Go back
    • Übersicht
    • Das EPA auf einen Blick
    • 50 Jahre EPÜ
      • Go back
      • Official celebrations
      • Übersicht
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kinderwettbewerb für kollektive Kunst
    • Rechtsgrundlagen und Mitgliedstaaten
      • Go back
      • Übersicht
      • Rechtsgrundlagen
      • Mitgliedstaaten
        • Go back
        • Übersicht
        • Mitgliedstaaten sortiert nach Beitrittsdatum
      • Erstreckungsstaaten
      • Validierungsstaaten
    • Verwaltungsrat und nachgeordnete Organe
      • Go back
      • Übersicht
      • Kommuniqués
        • Go back
        • 2024
        • Übersicht
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Kalender
      • Dokumente und Veröffentlichungen
        • Go back
        • Übersicht
        • Dokumente des Engeren Ausschusses
      • Verwaltungsrat
        • Go back
        • Übersicht
        • Zusammensetzung
        • Vertreter
        • Geschäftsordnung
        • Kollegium der Rechnungsprüfer
        • Sekretariat
        • Nachgeordnete Organe
    • Grundsätze
      • Go back
      • Übersicht
      • Auftrag, Vision und Werte
      • Strategieplan 2028
        • Go back
        • Treiber 1: Personal
        • Treiber 2: Technologien
        • Treiber 3: Qualitativ hochwertige Produkte und Dienstleistungen
        • Treiber 4: Partnerschaften
        • Treiber 5: Finanzielle Nachhaltigkeit
      • Auf dem Weg zu einer neuen Normalität
      • Datenschutzerklärung
    • Führung und Management
      • Go back
      • Übersicht
      • Über den Präsidenten
      • Managementberatungsausschuss
    • Nachhaltigkeit beim EPA
      • Go back
      • Overview
      • Umwelt
        • Go back
        • Overview
        • Inspirierende Erfindungen für die Umwelt
      • Soziales
        • Go back
        • Overview
        • Inspirierende soziale Erfindungen
      • Governance und finanzielle Nachhaltigkeit
    • Beschaffung
      • Go back
      • Übersicht
      • Beschaffungsprognose
      • Das EPA als Geschäftspartner
      • Beschaffungsverfahren
      • Veröffentlichungen des Dynamischen Beschaffungssystems
      • Nachhaltiger Beschaffungsstandard
      • Über eTendering
      • Rechnungsstellung
      • Beschaffungsportal
        • Go back
        • Übersicht
        • Elektronische Signatur von Verträgen
      • Allgemeine Bedingungen
      • Archivierte Ausschreibungen
    • Dienste & Aktivitäten
      • Go back
      • Übersicht
      • Unsere Dienste & Struktur
      • Qualität
        • Go back
        • Übersicht
        • Grundlagen
          • Go back
          • Übersicht
          • Europäisches Patentübereinkommen
          • Richtlinien für die Prüfung
          • Unsere Bediensteten
        • Qualität ermöglichen
          • Go back
          • Übersicht
          • Stand der Technik
          • Klassifikationssystem
          • Tools
          • Qualitätssicherung
        • Produkte & Dienstleistungen
          • Go back
          • Übersicht
          • Recherche
          • Prüfung
          • Einspruch
          • Fortlaufende Verbesserung
        • Qualität durch Netzwerke
          • Go back
          • Übersicht
          • Nutzerengagement
          • Zusammenarbeit
          • Befragung zur Nutzerzufriedenheit
          • Stakeholder-Qualitätssicherungspanels
        • Charta für Patentqualität
        • Qualitätsaktionsplan
        • Qualitäts-Dashboard
        • Statistik
          • Go back
          • Übersicht
          • Recherche
          • Prüfung
          • Einspruch
        • Integriertes Management beim EPA
      • Charta unserer Kundenbetreuung
      • Nutzerkonsultation
        • Go back
        • Übersicht
        • Ständiger Beratender Ausschuss beim EPA
          • Go back
          • Übersicht
          • Ziele
          • Der SACEPO und seine Arbeitsgruppen
          • Sitzungen
          • Bereich für Delegierte
        • Befragungen
          • Go back
          • Übersicht
          • Methodik
          • Recherche
          • Sachprüfung, abschließende Aktionen und Veröffentlichung
          • Einspruch
          • Formalprüfung
          • Kundenbetreuung
          • Einreichung
          • Key Account Management (KAM)
          • EPA-Website
          • Archiv
      • Europäische und internationale Zusammenarbeit
        • Go back
        • Übersicht
        • Zusammenarbeit mit den Mitgliedstaaten
          • Go back
          • Übersicht
        • Bilaterale Zusammenarbeit mit Nichtmitgliedstaaten
          • Go back
          • Übersicht
          • Validierungssystem
          • Programm für verstärkte Partnerschaft
        • Internationale Organisationen, Trilaterale und IP5
        • Zusammenarbeit mit internationalen Organisationen außerhalb des IP-Systems
      • Europäische Patentakademie
        • Go back
        • Übersicht
        • Partner
      • Chefökonom
        • Go back
        • Übersicht
        • Wirtschaftliche Studien
      • Ombudsstelle
      • Meldung von Fehlverhalten
    • Beobachtungsstelle für Patente und Technologie
      • Go back
      • Übersicht
      • Innovation gegen Krebs
      • Akteure im Innovationsbereich
        • Go back
        • Übersicht
        • Start-ups und KMU
      • Politisches Umfeld und Finanzierung
        • Go back
        • Übersicht
        • Programm zur Innovationsfinanzierung
          • Go back
          • Übersicht
          • Unsere Studien zur Innovationsfinanzierung
          • EPA-Initiativen für Patentanmelder/innen
          • Programm zur Innovationsfinanzierung
        • Patente und Normen
          • Go back
          • Übersicht
          • Publikationen
          • Patent standards explorer
      • Tools
        • Go back
        • Übersicht
        • Deep Tech Finder
      • Über die Beobachtungsstelle
        • Go back
        • Übersicht
        • Arbeitsplan
    • Transparency portal
      • Go back
      • Übersicht
      • Allgemein
        • Go back
        • Übersicht
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Übersicht
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Humankapital
      • Umweltkapital
      • Organisationskapital
      • Sozial- und Beziehungskapital
      • Wirtschaftskapital
      • Governance
    • Statistics and trends
      • Go back
      • Übersicht
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • Geschichte
      • Go back
      • Übersicht
      • 1970er-Jahre
      • 1980er-Jahre
      • 1990er-Jahre
      • 2000er-Jahre
      • 2010er-Jahre
      • 2020er Jahre
    • Kunstsammlung
      • Go back
      • Übersicht
      • Die Sammlung
      • Let's talk about art
      • Künstler
      • Mediathek
      • What's on
      • Publikationen
      • Kontakt
      • Kulturraum A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Frühere Ausstellungen
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Lange Nacht"
  • Beschwerdekammern
    • Go back
    • Übersicht
    • Entscheidungen der Beschwerdekammern
      • Go back
      • Neue Entscheidungen
      • Übersicht
      • Ausgewählte Entscheidungen
    • Mitteilungen der Beschwerdekammern
    • Verfahren
    • Mündliche Verhandlungen
    • Über die Beschwerdekammern
      • Go back
      • Übersicht
      • Präsident der Beschwerdekammern
      • Große Beschwerdekammer
        • Go back
        • Übersicht
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technische Beschwerdekammern
      • Juristische Beschwerdekammer
      • Beschwerdekammer in Disziplinarangelegenheiten
      • Präsidium
        • Go back
        • Übersicht
    • Verhaltenskodex
    • Geschäftsverteilungsplan
      • Go back
      • Übersicht
      • Technical boards of appeal by IPC in 2025
      • Archiv
    • Jährliche Liste der Verfahren
    • Mitteilungen
    • Jahresberichte
      • Go back
      • Übersicht
    • Veröffentlichungen
      • Go back
      • Abstracts of decisions
    • Rechtsprechung der Beschwerdekammern
      • Go back
      • Übersicht
      • Archiv
  • Service & Unterstützung
    • Go back
    • Übersicht
    • Aktualisierungen der Website
    • Verfügbarkeit der Online-Dienste
      • Go back
      • Übersicht
    • FAQ
      • Go back
      • Übersicht
    • Veröffentlichungen
    • Bestellung
      • Go back
      • Patentwissen – Produkte und Dienste
      • Übersicht
      • Allgemeine Geschäftsbedingungen
        • Go back
        • Übersicht
        • Patentinformationsprodukte
        • Massendatensätze
        • Open Patent Services (OPS)
        • Leitfaden zur fairen Nutzung
    • Verfahrensbezogene Mitteilungen
    • Nützliche Links
      • Go back
      • Übersicht
      • Patentämter der Mitgliedstaaten
      • Weitere Patentämter
      • Verzeichnisse von Patentvertretern
      • Patentdatenbanken, Register und Patentblätter
      • Haftungsausschluss
    • Aboverwaltung
      • Go back
      • Übersicht
      • Anmelden
      • Einstellungen verwalten
      • Abmelden
    • Veröffentlichungen
      • Go back
      • Übersicht
      • Möglichkeiten der Einreichung
      • Standorte
    • Offizielle Feiertage
    • Glossar
    • RSS-Feeds
Board of Appeals
Decisions

Recent decisions

Übersicht
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Startseite
  2. Node
  3. T 0574/96 (Deoxytetracyclines/AMERICAN CYANAMID) 30-07-1999
Facebook X Linkedin Email

T 0574/96 (Deoxytetracyclines/AMERICAN CYANAMID) 30-07-1999

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:1999:T057496.19990730
Datum der Entscheidung:
30 July 1999
Aktenzeichen
T 0574/96
Antrag auf Überprüfung von
-
Anmeldenummer
92114281.6
IPC-Klasse
C07C 237/26
Verfahrenssprache
EN
Verteilung
DISTRIBUTED TO BOARD CHAIRMEN AND MEMBERS (B)

Download und weitere Informationen:

Entscheidung in EN 156.37 KB
Alle Dokumente zum Beschwerdeverfahren finden Sie im Europäisches Patentregister
Bibliografische Daten verfügbar in:
EN
Fassungen
Nicht veröffentlicht
Bezeichnung der Anmeldung

Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines

Name des Anmelders
AMERICAN CYANAMID COMPANY
Name des Einsprechenden
-
Kammer
3.3.01
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 84 1973
European Patent Convention Art 111(1) 1973
Schlagwörter
Clarity (yes) - complex claims not unclear
Orientierungssatz
Clarity under Article 84 EPC is not at stake in a case of mere complexity of a claim, provided the subject-matter for which protection is sought and the scope thereof are clear and unambiguous for a person skilled in the art, either per se or in the light of the description, since complexity as such is not equivalent to lack of clarity.
Angeführte Entscheidungen
-
Anführungen in anderen Entscheidungen
T 1020/98

Summary of Facts and Submissions

I. The appeal lodged on 28 March 1996 lies from the decision of the Examining Division posted on 30. January 1996 refusing European patent application No. 92 114 281.6 (European publication No. 0 536 515).

II. The decision of the Examining Division was based on claims 1 to 20 of the application as filed and annexed thereto. Claims 1 and 11 read as follows:

"1. A compound of the formula:

FORMULA

wherein:

X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; and when X = NR1R2 and R1 = hydrogen,

R2 = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when R1 = methyl or ethyl,

R2 = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R1 = n-propyl,

R2 = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R1 = 1-methylethyl,

R2 = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R1 = n-butyl,

R2 = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R1 = 1-methylpropyl,

R2 = 2-methylpropyl;

R is selected from R4(CH2)nCO- or R4'(CH2)nSO2-;

and when R = R4(CH2)nCO- and n=0,

R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; alpha-amino-(C1-C4)alkyl group selected from aminomethyl, alpha-aminoethyl, alpha-aminopropyl or alpha-aminobutyl; carboxy(C2-C4)-alkylamino group selected from aminoacetic acid, alpha-aminobutyric acid or alpha-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; alpha-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, alpha-hydroxyethyl or alpha-hydroxy-1-methylethyl or alpha-hydroxypropyl; alpha-mercapto(C1-C3)alkyl group selected from mercaptomethyl, alpha-mercaptoethyl, alpha-mercapto-1-methylethyl or alpha-mercaptopropyl; halo(C1-C3)alkyl group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto: FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, alpha-naphthyl, beta-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ]; (C1-C4)alkoxy group; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, alpha-naphthyl or beta-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R = R4(CH2)nCO- and n=1-4, R4 is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcar- bonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; (C1-C4)alkoxy group; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino); (C7-C10)aralkyloxy group; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C8)aralkylthio group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O,S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; (C2-C5)azacycloalkyl group; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, alpha-aminopropionic acid, alpha-aminobutyric acid and their optical isomers; alpha-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, alpha-hydroxyethyl or alpha-hydroxy-1-methylethyl or alpha-hydroxypropyl; halo(C1-C3) alkyl group; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-ar yl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or

-(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)n, n=2-6, or

-(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R = R4'(CH2)nSO2- and n = 0, R4' is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group; halo(C1-C3)alkyl group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto: FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or

-(CH2)2W-(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R = R4'(CH2)nSO2- and n= 1-4, R4' is selected from hydrogen; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy group; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)n- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio or n-propylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C8)aralkylthio group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O,S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; hydroxy group, mercapto group; mono- or di- straight or branched (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; halo(C1-C3)alkyl group; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; (C7-C9)aralkyl group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom: FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; or -(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; (C7-C9)aralkyl group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; or -(CH2)nCOOR7' where n=0-4 and R7' is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, alpha-naphthyl or beta-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are -(CH2)2W(CH2)2-, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl [straight or branched], -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

11. The compound according to Claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide sulfate; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide monohydrochloride; [4S-(4alpha,12aalpha)]-9-(Acetylamino)-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)] -4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(trifluoroacetyl)amino]-2- naphthacenecarboxamide sulfate; [4S-(4alpha, 12aalpha)]-7-(Diethylamino)-4-(dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamidesulfate (1:2); [4S-(4alpha,12aalpha)]-9-(Acetylamino)-7- (diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide sulfate (1:2); [4S-(4alpha,12aalpha)]-7-(Diethylamino)-4- (dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide; [4S-(4alpha, 12aalpha)]-9-(Acetylamino)-7-(diethylamino)-4- (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydrox y-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)] -4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7- iodo-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2- naphthacenecarboxamide sulfate; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-9- [(methoxyacetyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; 4S-(4alpha,12aalpha)]-9- [(4-Bromo-1-oxobutyl)amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; 4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(1-oxo-2-propenyl)amino]-2- naphthacenecarboxamide; 4S-(4alpha,12aalpha)]-9- [[(Acetyloxy)acetyl]amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide sulfate; 4S-(4alpha, 12aalpha)]-9-(Benzoylamino)-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11, 2a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; 4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(4-methoxybenzoyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha))]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(2-methylbenzoyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[(2-fluorobenzoyl) amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(pentafluorobenzoyl)amino]-1,11-dioxo-2- naphthacenecarboxamide hydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-9-[[3-(trifluoromethyl) benzoyl]amino]-2-naphthacenecarboxamide;

[4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [(2-furanylcarbonyl)amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy1,11-dioxo-9- [(2-thienylcarbonyl)amino]-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(4-nitrobenzoyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 9-[(4-Aminobenzoyl)amino]-4,7-bis- dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamidesulfate; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-9-[[(4- dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide; [7S-(7alpha, 10aalpha)]-[2-[[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester; [4S-(4alpha,12aalpha)]- 9-[(Aminoacetyl)amino]-4,7-bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono(trifluoroacetate); [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(phenylsulfonyl)amino]-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-9-[[(4-Chlorophenyl) sulfonyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5, 5a,6,11,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9-[(3- nitrophenyl)sulfonyl]amino-1,11-dioxo-2- naphthacenecaboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9-[[(4- nitrophenyl)sulfonyl]amino]-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4alpha,12a alpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(2-thienylsulfon [4S-(4alpha,12aalpha)]-9[[(2- (Acetylamino)-4-methyl-5-thiazolylsulfonyl]amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[(ethylsulfonyl)amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (formylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-1,11-dioxo-N-(1- pyrrolidinylmethyl)-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-9-[(methanesulfonyl)amino]-1,11- dioxo-2-naphthacenecarboxamide; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-9-[[(phenylmethoxy)acetyl]amino]-2- naphthacenecarboxamide; [7S-(7alpha,10aalpha)]- [[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a, 6,6a,7,10,10a,12-octahydro-1,8,10a,11- tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]oxoacetic acid ethyl ester; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(hydroxyacetyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[[(methylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboximide hydrochloride; [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9- (acetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2- naphthacenecarboxamide sulfate; [7S(7alpha, 10aalpha)]-[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid methyl ester; [7S-(7alpha,10aalpha)]-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid (2-diethylamino)ethyl ester; [7S-(7alpha,10aalpha)][9-(Aminocarbonyl)- 4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid ethenyl ester; [7S- (7alpha,10aalpha)]-[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid 2-propenyl ester; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide sulfate; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-9-[(methoxyacetyl)amino]-1,11-dioxo- 2-naphthacenecarboxamide hydrochloride; [4S-(4alpha,12aalpha)]-9-[(4-Bromo-1-oxobutyl) amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide sulfate; [4S-(4alpha,12aalpha)]-9-[[(Acetyloxy)acetyl] amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide; [4S-(4alpha, 12aalpha)]-9-(Benzoylamino)-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide sulfate; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-9-[[3-(trifluoromethyl)benzoyl]amino]-2- naphthacenecarboxamide hydrochloride; [4S- (4alpha,12aalpha)]-9-[(4-Aminobenzoyl)amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[[(4-dimethylamino) benzoyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide hydrochloride; [7S- (7alpha,10aalpha)]-[2-[[9-(Aminocarbonyl)-4, 7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester hydrochloride; [4S- (4alpha,12aalpha]-9-[(Aminoacetyl)amino]-4,7-bis- dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[(ethylsulfonyl)amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-9-[(methanesulfonyl) amino]-1,11-dioxo-2-naphthacenecarboxamide sulfate; [4S-(4alpha,12aalpha)]-4,7-Bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [[(phenylmethoxy)acetyl]amino]-2- naphthacenecarboxamide hydrochloride; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 9-[(hydroxyacetyl)amino]-1,11-dioxo-2- naphthacenecarboxamide sulfate; [4S-(4alpha, 12aalpha)]-4-(Dimethylamino)-9-(acetylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-7-iodo-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [7S-(7alpha,10aalpha)]- [9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6, 6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester sulfate; [7S-(7alpha,10aalpha)]-[9- (Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a, 7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]carbamic acid (2-diethylamino)ethyl ester hydrochloride; [7S-(7alpha,10aalpha)]-[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid ethenyl ester sulfate; [7S-(7alpha,10aalpha)]-[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid 2-propenyl ester hydrochloride; [4S-(4alpha,12aalpha]-4,7-Bis (dimethylamino)-9-[[(diethylamino)acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate; [4S(4alpha,12aalpha]-4,7-Bis (dimethylamino)-9-[[(diethylamino)acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride; [4S-(4alpha,12aalpha]-4,7-Bis (dimethylamino)-9-[[(diethylamino)acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (chloroacetylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-9- [(Chloroacetyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-9- [(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-9- [(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (free base); [4S-(4alpha,12aalpha)]-9- [(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide; [4S-(4alpha,12aalpha)]-9- [(2-Bromo-1-oxopropyl)amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide hydrobromide; [4S- (4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide hydrobromide; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-9- [[(methylamino)acetyl]amino]-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride; [7S- (7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]-4-morpholineacetamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-9-[[(ethylamino)acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-9- [[(Cyclopropylamino)acetyl]amino]-4,7- bis(dimethylamino)-1,4,4a,5,5a,6,11,12aoctahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(butylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-9-[[(Diethylamino)acetyl] amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]-1-pyrrolidineacetamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [[[(2-methylpropyl)amino]acetyl]amino]-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]-1-piperidineacetamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[9- (Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a, 7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-1H-imidazole-1-acetamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [[(propylamino)acetyl]amino]-2- naphthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[2-(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-napthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [[2-(methylamino)-1-oxopropyl]amino]-1,11-dioxo- 2-naphthacenecarboxamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]-alpha-methyl-1-pyrrolidineacetamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-9-[[4-(dimethylamino)-1- oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- napthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-9-[[(Butylmethylamino)acetyl] amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-9-[[(pentylamino)acetyl] amino]-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-9-[[[(phenylmethyl)amino]acetyl]amino] -2-naphthacenecarboxamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[2-[[9- (Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a, 7,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12- dioxo-2-naphthacenyl]amino]-2-oxoethyl]glycine; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-N-(1-pyrrolidinylmethyl)-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-N-(4- morpholinylmethyl)-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-N-(1-piperidinylmethyl)-2- naphthacenecarboxamide; [7S-(7alpha,10aalpha)]-N- [9-(Aminocarbonyl-4,7-bis(dimethylamino)-5,5a,6, 6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-napthacenyl]-1-azetidineacetamide; [4S-(4alpha,12aalpha)]-9-[[(Cyclobutylamino) acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide hydrochloride."

III. The Examining Division held that claims 1 and 11 did not meet the requirements of Article 84 EPC. More particularly, the Examining Division considered claim 1 to be unclear since it was not possible to establish with absolute certainty within a reasonable time whether any single compound fell within the scope of that claim due to Markush formulae formulated in a complex manner. Problems arose from the enormous length of the claim, the large number of variables often defined in terms of further variables and the manifold provisos. To combine these features caused the mental processes, which determined whether a compound was covered by the claim, to break down in confusion rendering it impossible for the claim to define the matter for which protection is sought. The complexity of a claim could not be increased indefinitely and still meet the requirements of Article 84 EPC. In such a case it must be possible to declare the claim prima facie unclear. With regard to claim 11 the long list of complex chemical names in that claim presented an undue burden on the person trying to establish whether a compound fell within the scope of that claim.

IV. The Appellant (Applicant) submitted that claims 1 and 11. did not lack clarity as stipulated by Article 84 EPC. More particularly, neither the complexity of the claims nor the time needed by a reader to establish whether or not a single compound fell within the scope of the claims were issues to be considered pursuant to Article 84 EPC. Claim 1 showed a clear and concise hierarchical construction which prevented any confusion of the skilled reader. The two polycyclic formulae of claim 1 had only four substituents (R, X, R5, R6). The substituent X had a very brief definition over 13 lines. The substituent R was defined hierarchically on the basis of the provisos:

(A) R = R4(CH2)nCO- and n=0, or

(B) R = R4(CH2)nCO- and n=1-4, or

(C) R = R4'(CH2)nSO2- and n = 0, or

(D) R = R4'(CH2)nSO2- and n= 1-4.

Those provisos were further defined on one to two pages each. Finally the substituents R5 and R6 were then defined on 3/4 of a page. Claim 11 had been written in accordance with standard chemical nomenclature which could not cause any lack of clarity.

V. The Appellant requested that the decision under appeal be set aside and that the case be remitted to the Examining Division for further prosecution. Auxiliarily he requested that oral proceedings be appointed in case the request was not held allowable.

Reasons for the Decision

1. The appeal is admissible.

2. The only issue arising from this appeal is whether or not claims 1 and 11 satisfy the requirement of clarity within the meaning of Article 84 EPC, which is stated in the decision under appeal as being the sole ground for refusal of the application.

3. Article 84 EPC

3.1. In the contested decision claim 1 comprising Markush-formulae has been objected to under the heading of clarity as being formulated in a so complex manner that it was impossible to establish within a reasonable time whether any single compound fell within the scope of that claim.

The Board observes that the European Patent Convention does not prescribe the absence of complexity from a claim as a legal requirement for a patent to be granted thereupon. The Board would also consider any such requirement as unreasonable, because if the nature of an invention to be patented is such that it cannot be claimed in a nutshell, this must be accepted.

For that reason, the Examining Division has based the objection to complexity on lack of clarity pursuant to Article 84 EPC. However, in the present case Article 84 EPC offers no basis for objecting that the claim is too complex. In the Board's judgement, complexity as such is not equivalent to lack of clarity. Clarity under Article 84 EPC is not at stake in a case of mere complexity of a claim provided the subject-matter for which protection is sought and the scope thereof are clear and unambiguous for a person skilled in the art, either per se or in the light of the description. Further, the Board cannot see from the decision under appeal what is meant by "within a reasonable time", apart from possibly that it takes longer than average to examine the subject-matter of the claim.

The Board noted furthermore that despite the rather unusual length of claim 1 the Examining Division did not challenge its conciseness, another requirement to be met under Article 84 EPC. Indeed Article 84 EPC cannot be construed in such a way that only inventions which are straightforward would have access to patent protection, whereas complex inventions would be locked out from that protection. It would be improper to refuse to examine that which applicants regard as their invention. This does not mean, however, that lack of conciseness could not arise in particular circumstances, since each case has to be decided on its own merits.

3.2. In the present case claim 1 is directed to compounds having either of two related polycyclic Markush-formulae indicated at the beginning of that claim on page 253, lines 5 to 15. Those formulae bear exclusively the four variable substituents X, R, R5 and R6 which are nested each one within another in a hierarchical order (see point II above). The key to the hierarchical order emerges from the ingenious use of semicolons, commas, round brackets and square brackets throughout that claim.

3.2.1. The substituent X is defined on page 253, lines 16 to 34 in a clear-cut hierarchical manner and has not been objected to in the decision under appeal. Thus, it is unnecessary for the Board to go into more detail on this matter.

3.2.2. The substituent R is defined on page 253, line 35 as representing either R4(CH2)nCO- or R4'(CH2)nSO2-, the respective substituents R4 and R4' and the index n being then specified each with respect to the following provisos:

(A) R = R4(CH2)nCO- and n=0 (page 253, line 36),

(B) R = R4(CH2)nCO- and n=1-4 (page 258, line 31),

(C) R = R4'(CH2)nSO2- and n = 0 (page 264, line 13), or

(D) R = R4'(CH2)nSO2- and n= 1-4 (page 266, line 18).

3.2.2.1. If proviso (A) applies, the substituent R4 is selected from the following list of first order starting with "hydrogen" on page 253, line 37 and ending with the "RaRbaminoxy group" on page 258, line 24 and indicating the alternative groups:

hydrogen; amino; monosubstituted amino; disubstituted amino; straight or branched (C1-C4)alkyl group; (C3-C6)cycloalkyl group; substituted (C3-C6)cycloalkyl group; (C6-C10)aryl group; substituted (C6-C10)aryl group; (C7-C9)aralkyl group ; alpha-amino-(C1-C4)alkyl group; carboxy(C2-C4)-alkylamino group; (C7-C9)aralkylamino group; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group; alpha-hydroxy(C1-C3)alkyl group; alpha-mercapto(C1-C3)alkyl group; halo(C1-C3)alkyl group; a heterocycle group; acyl or haloacyl group; (C1-C4)alkoxycarbonyl group; vinyl or substituted vinyl group; (C1-C4)alkoxy group; C6-aryloxy group; (C7-C10)aralkyloxy group; vinyloxy or substituted vinyloxy group; RaRbamino(C1-C4)alkoxy group; or RaRbaminoxy group.

3.2.2.1.1. Numerous groups of that list of first order are more narrowly defined by making a further selection from particular lists of second order consisting each of specific alternative groups.

For example, the "heterocyle group" comprised in the list of first order is to be selected from the list of second order starting on page 254, line 32, and ending on page 256, line 5, and consisting of five alternative groups, i.e. a five membered aromatic or saturated ring with one N, O, S or Se heteroatom as defined in two particular formulae, or a five membered aromatic ring with two N, O, S or Se heteroatoms as defined in two particular formulae, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom as defined in three particular formulae, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom.

The "acyl or haloacyl group" comprised in the list of first order is to be selected from the list of second order starting with the "acetyl" group on page 256, line 6, and ending with the "(heterocycle)carbonyl" group on page 256, line 10.

The substitution of the "substituted vinyl" group comprised in the list of first order is to be selected from the list of second order starting with the "(C1-C3)alkyl" group on page 257, line 24, and ending with the "heterocycle group" on page 257, line 30.

The substituents Ra and Rb contained in both "RaRbamino(C1-C4)alkoxy" and "RaRbaminoxy" groups of the list of first order, are defined in lists of second order as representing either a "straight or branched (C1-C4)alkyl" group (page 258, lines 18 and 25), or a "(CH2)n" group (page 258, lines 20 and 27), or a "-(CH2)2W(CH2)2-" group (page 258, lines 21 and 28).

3.2.2.1.2. Some groups of those lists of second order are more narrowly defined by making a further selection from particular lists of third order consisting each of specific alternative groups.

For example, the heterocycle of the "(heterocycle)carbonyl" group comprised in the list of second order on page 256, line 10, is to be selected from the list of third order starting on page 256, line 10, and ending on page 257, line 20, and consisting of five alternative groups, i.e. a five membered aromatic or saturated ring with one N, O, S or Se heteroatom as defined in two particular formulae, or a five membered aromatic ring with two N, O, S or Se heteroatoms as defined in two particular formulae, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom as defined in three particular formulae, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom.

The substitution of the "substituted (C6-C10)-aryl group" comprised in the list of second order on page 257, lines 26 and 27, is to be selected from the list of third order starting with "halo" on page 257, line 27, and ending with the "carboxy" group on page 257, line 29.

The "heterocycle group" comprised in the list of second order on page 257, line 30 is to be selected, in third order, from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom as defined in two particular formulae.

The group W of the "-(CH2)2W(CH2)2-" group comprised in the list of second order on page 258, lines 21 and 28 is to be selected from the lists of third order on page 258, lines 21 and 22 and page 258, lines 28 and 29 respectively, consisting of five alternative groups, i.e. -N(C1-C3)alkyl, -NH, -NOB, O or S.

3.2.2.1.3. Very few groups of those lists of third order are even more narrowly defined by making a further selection from particular lists of fourth order consisting each of specific alternative groups.

For example, the group B of the "NOB" group comprised in the list of third order on page 258, lines 22 and 28 is to be selected from the list of fourth order on page 258, lines 23 and 29, i.e. hydrogen or (C1-C3)alkyl.

3.2.2.2. If proviso (B) applies, the substituent R4 is selected from the following list of first order starting with "hydrogen" on page 258, line 31 and ending with the "RaRbaminoxy group" on page 264, line 4 and indicating the alternative groups:

hydrogen; amino; straight or branched (C1-C4)alkyl group; (C3-C6)cycloalkyl group; substituted (C3-C6)cycloalkyl group; (C6-C10)aryl group; substituted(C6-C10)aryl group; (C7-C9)aralkyl group; acyloxy or haloacyloxy group; (C1-C4)alkoxy group; C6-aryloxy group; (C7-C10)aralkyloxy group; (C1-C3)alkylthio group; C6-arylthio group; C6-arylsulfonyl group; (C7-C8)aralkylthio group; a heterocycle group; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group; (C2-C5)azacycloalkyl group; carboxy(C2-C4)alkylamino group; alpha-hydroxy(C1-C3)alkyl group; halo(C1-C3) alkyl group; acyl or haloacyl group; (C1-C4)alkoxycarbonylamino group; (C1-C4)alkoxycarbonyl group; RaRbamino(C1-C4)alkoxy group; or RaRbaminoxy group.

Those groups are then to be selected from further lists of second, third and fourth order in accordance with the hierarchical key set out in points 3.2.2.1.1 to 3.2.2.1.3 above.

3.2.2.3. If proviso (C) applies, the substituent R4' is selected from the following list of first order starting with "amino" on page 264, line 13 and ending with the "RaRbaminoxy group" on page 266, line 10 and indicating the alternative groups:

amino; monosubstituted amino; disubstituted amino; straight or branched (C1-C4)alkyl group; (C3-C6)cycloalkyl group; substituted (C3-C6)cycloalkyl group; (C6-C10)aryl group; substituted (C6-C10)aryl group; (C7-C9)aralkyl group; halo(C1-C3)alkyl group; a heterocycle group; RaRbamino(C1-C4)alkoxy group; or RaRbaminoxy group.

Those groups are then to be selected from further lists of second, third and fourth order in accordance with the hierarchical key set out in points 3.2.2.1.1 to 3.2.2.1.3 above.

3.2.2.4. If proviso (D) applies, the substituent R4' is selected from the following list of first order starting with "hydrogen" on page 266, line 18 and ending with the "(C1-C4)alkoxycarbony group" on page 270, line 13 and indicating the alternative groups:

hydrogen; straight or branched (C1-C4)alkyl group; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group; substituted (C3-C6)cycloalkyl group; (C6-C10)aryl group; substituted (C6-C10)aryl group; (C7-C9)aralkyl group; (C1-C4)alkoxy group; C6-aryloxy group; (C7-C10)aralkyloxy group; RaRbamino(C1-C4)alkoxy group; RaRbaminoxy group; (C1-C3)alkylthio group; C6-arylthio group; (C7-C8)aralkylthio group; a heterocycle group; hydroxy group; mercapto group; mono- or di- straight or branched (C1-C6)alkylamino group; halo(C1-C3)alkyl group; acyl or haloacyl group; or (C1-C4)alkoxycarbonyl group.

Those groups are then to be selected from further lists of second, third and fourth order in accordance with the hierarchical key set out in points 3.2.2.1.1 to 3.2.2.1.3 above.

3.2.3. The substituents R5 and R6 are defined on page 270, line 17 to page 273, line 16 following the same hierarchical order as set out in point 3.2.2.1 above in detail.

3.3. Therefore, claim 1 defines for a person skilled in the art clearly and unambiguously the subject-matter for which protection is sought and the scope thereof due to the hierarchical construction followed throughout that claim.

3.4. In the contested decision dependent claim 11 has been objected to under the heading of clarity since it comprised a long list of complex chemical names.

However, the chemical names objected to are drafted in accordance with the standards for chemical nomenclature conventional in the art. Therefore, they reveal unambiguously the corresponding chemical compounds to the person skilled in the art without any remaining unclarity.

3.5. For these reasons, in the Board's judgement, neither claim 1 nor claim 11 can be challenged with respect to clarity solely for their complexity and the Board concludes that those claims meet to that extent the requirements of Article 84 EPC.

4. In these circumstances, the examination not having been concluded and in view of the Appellant having requested remittal, the Board exercises its power under Article 111 (1) EPC to remit the case to the Examining Division for further prosecution.

5. When resuming examination proceedings, the Examining Division may consider whether or not example 132 is within the scope of claim 1 and whether or not the term "acyloxy or haloacyloxy group" on page 259, line 6 is correct, both objections having been noted in the decision under appeal, but not forming part of the reasons of the decision. Moreover, the Examining Division is directed to consider the matter whether or not the definition given inter alia on page 255, lines 20. to 22, which comprises a reference to S and Se heteroatoms, is consistent with the three heterocyclic formulae that follow in the claim.

6. Since the Appellant's main request succeeds there is no need for the Board to consider its auxiliary request for oral proceedings.

Entscheidungsformel

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the first instance for further prosecution.

Footer - Service & support
  • Unterstützung
    • Aktualisierungen der Website
    • Verfügbarkeit der Online-Dienste
    • FAQ
    • Veröffentlichungen
    • Verfahrensbezogene Mitteilungen
    • Kontakt
    • Aboverwaltung
    • Offizielle Feiertage
    • Glossar
Footer - More links
  • Jobs & Karriere
  • Pressezentrum
  • Single Access Portal
  • Beschaffung
  • Beschwerdekammern
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Impressum
  • Nutzungsbedingungen
  • Datenschutz
  • Barrierefreiheit